Domain Therapeutics to present and participate at major global healthcare conferences, March to June 2025

Domain’s leadership will highlight advancements in its key programs in immuno-oncology and inflammation
Key presentations on its first-in-class biased antagonist of PAR2 and best-in-class Treg-depleting anti-CCR8 antibody candidates

Strasbourg, France – Montreal, Canada – Boston, United States, February 27, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for patients, today announces its participation and presentation in a series of forthcoming high-profile healthcare conferences.

The Company’s expert leadership team will showcase its latest progress and upcoming catalysts driven by its first-in-class biased antagonist of PAR2 and best-in-class Treg-depleting anti-CCR8 antibody. Leveraging its robust pipeline of highly differentiated clinical and preclinical GPCR-targeting therapies, Domain continues to drive innovation in areas of high unmet medical need.

BIO-Europe Spring – March 17-19
Location: Milan, Italy

American Association for Cancer Research Annual Meeting (AACR) – April 25-30
Location: Chicago, USA

Poster presentations: PAR2, CCR8, and EP4 candidates to be announced

4th GPCR Targeted Drug Discovery Summit – May 22-24
Location: Boston, USA

Fireside chat: Thursday, May 22, 09:30 EDT
Fireside chat topic: Uncovering Tools to Discover Synthetic Ligands for Orphan GPCRs to Advance the Development of Effective Therapies
Speaker: Laurent Sabbagh, Scientific Director Biology
Presentation: Thursday, May 22, 13:15 EDT
Presentation topic: Leveraging Effective Models for Anti-CCR8 Antibody to Inform First In-Human Clinical Trials
Presenter: Stephan Schann, Chief Scientific Officer

American Society of Clinical Oncology (ASCO) – May 30-June 3
Location: Chicago, USA

Jefferies Healthcare Conference – June 3-5
Location: New York, USA

BIO International – June 16-19
Location: Boston, USA

For more information or to arrange a meeting with Domain Therapeutics at these events, please contact domain@optimumcomms.com.

ENDS

For more information, please contact:
Optimum Strategic Communications
Mary Clark, Zoe Bolt, Elena Bates
+44 (0) 203 882 9621
domain@optimumcomms.com